Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells.

Graham MK, Kim J, Da J, Brosnan-Cashman JA, Rizzo A, Baena Del Valle JA, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner MC, De Marzo AM, Meeker AK, Heaphy CM.

Mol Cancer Res. 2019 Dec;17(12):2480-2491. doi: 10.1158/1541-7786.MCR-19-0654. Epub 2019 Oct 14.

PMID:
31611308
2.

Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.

Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA.

Nat Med. 2019 Oct;25(10):1627. doi: 10.1038/s41591-019-0573-5.

PMID:
31501535
3.

Telomere alterations in neurofibromatosis type 1-associated solid tumors.

Rodriguez FJ, Graham MK, Brosnan-Cashman JA, Barber JR, Davis C, Vizcaino MA, Palsgrove DN, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noƫ M, Wood LD, Pratilas CA, Morris CD, Belzberg A, Blakeley J, Heaphy CM.

Acta Neuropathol Commun. 2019 Aug 28;7(1):139. doi: 10.1186/s40478-019-0792-5.

4.

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.

Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA.

Nat Med. 2019 Aug;25(8):1260-1265. doi: 10.1038/s41591-019-0493-4. Epub 2019 Jul 1. Erratum in: Nat Med. 2019 Oct;25(10):1627.

5.

Genetic alterations associated with ALTered telomeres.

Brosnan-Cashman JA, Graham MK, Heaphy CM.

Oncotarget. 2018 Sep 18;9(73):33739-33740. doi: 10.18632/oncotarget.26111. eCollection 2018 Sep 18. No abstract available.

6.

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.

Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK.

PLoS One. 2018 Sep 18;13(9):e0204159. doi: 10.1371/journal.pone.0204159. eCollection 2018.

7.

Personalized postdoctoral fellowship care.

Graham MK, Park BH, Wyhs N.

Nat Biotechnol. 2018 Sep 6;36(9):900-902. doi: 10.1038/nbt.4228. No abstract available.

PMID:
30188527
8.

Comparison of three clinical facilitation models for midwifery students undertaking clinical placement in south Australia.

McKellar L, Fleet J, Vernon R, Graham MK, Cooper M.

Nurse Educ Pract. 2018 Sep;32:64-71. doi: 10.1016/j.nepr.2018.07.010. Epub 2018 Jul 17.

PMID:
30048832
9.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

10.

Telomeres and telomerase in prostate cancer development and therapy.

Graham MK, Meeker A.

Nat Rev Urol. 2017 Oct;14(10):607-619. doi: 10.1038/nrurol.2017.104. Epub 2017 Jul 4. Review.

11.

Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.

VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH, Heaphy CM.

Cancer Cytopathol. 2017 Jul;125(7):544-551. doi: 10.1002/cncy.21857. Epub 2017 Apr 3.

12.

Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone.

Graham MK, Principessa L, Antony L, Meeker AK, Isaacs JT.

Prostate. 2017 Mar;77(4):374-384. doi: 10.1002/pros.23276. Epub 2016 Nov 8.

13.

Targeting the human androgen receptor gene with platinated triplex-forming oligonucleotides.

Graham MK, Brown TR, Miller PS.

Biochemistry. 2015 Apr 7;54(13):2270-82. doi: 10.1021/bi501565n. Epub 2015 Mar 25.

PMID:
25768916
14.

Inhibition of transcription by platinated triplex-forming oligonucleotides.

Graham MK, Miller PS.

J Biol Inorg Chem. 2012 Dec;17(8):1197-208. doi: 10.1007/s00775-012-0933-9. Epub 2012 Sep 11.

PMID:
22965663
15.

Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure.

Teeguarden JG, Calafat AM, Ye X, Doerge DR, Churchwell MI, Gunawan R, Graham MK.

Toxicol Sci. 2011 Sep;123(1):48-57. doi: 10.1093/toxsci/kfr160. Epub 2011 Jun 24.

PMID:
21705716
16.

Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes.

Leckie AM, Graham MK, Grant JB, Ritchie PJ, Frier BM.

Diabetes Care. 2005 Jun;28(6):1333-8.

PMID:
15920048
17.

Second messengers mediating mechanical responses to the FARP GYIRFamide in the fluke Fasciola hepatica.

Graham MK, Fairweather I, McGeown JG.

Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2089-94.

18.

Ionic mechanisms underlying spontaneous muscle contractions in the liver fluke, Fasciola hepatica.

Graham MK, McGeown JG, Fairweather I.

Am J Physiol. 1999 Aug;277(2):R374-83. doi: 10.1152/ajpregu.1999.277.2.R374.

PMID:
10444543
19.

The effects of FaRPs on the motility of isolated muscle strips from the liver fluke, Fasciola hepatica.

Graham MK, Fairweather I, McGeown JG.

Parasitology. 1997 May;114 ( Pt 5):455-65.

PMID:
9149416
20.

Quantitative autoradiographic evidence for insulin receptors in the choroid plexus of the rat brain.

Baskin DG, Brewitt B, Davidson DA, Corp E, Paquette T, Figlewicz DP, Lewellen TK, Graham MK, Woods SG, Dorsa DM.

Diabetes. 1986 Feb;35(2):246-9.

PMID:
3510931

Supplemental Content

Loading ...
Support Center